Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
22 hedge funds and large institutions have $31.6M invested in Iterum Therapeutics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 2.99% → 2.97% (-0.02%)
25% less capital invested
Capital invested by funds: $42.3M → $31.6M (-$10.7M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$41.6K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$9.75K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$3.12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$852 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hound Partners
New York
|
-$129K |
| 2 |
Millennium Management
New York
|
-$101K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$69.2K |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$27.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$15.2K |
ITRM Hedge Fund Activity: Q4 2018 in Review
22 of the 4,456 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q4 2018, worth a combined $31.6M — down 25% from $42.3M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ITRM positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $41.6K. The largest seller was Hound Partners, exiting entirely with an estimated $129K sold.
- 22 institutional investors held Iterum Therapeutics (ITRM) as of Q4 2018, up from 21 in Q3 2018.
- Funds reported $31.6M of Iterum Therapeutics stock for Q4 2018, down 25% quarter-over-quarter.
- 2 funds opened new Iterum Therapeutics positions in Q4 2018 and 1 closed out, a net change of +1 holder.
- The largest Iterum Therapeutics buyer in Q4 2018 was Royal Bank of Canada, an estimated $41.6K added.
- The largest Iterum Therapeutics seller in Q4 2018 was Hound Partners, an estimated $129K sold.
Based on aggregated 13F filings for Q4 2018.